Nautilus Biotechnology(NAUT) - 2024 Q3 - Quarterly Results

Financial Performance - Net loss for Q3 2024 was $16.4 million, compared to a net loss of$15.9 million in Q3 2023[4] - Operating expenses for Q3 2024 were $19.1 million, flat compared to Q3 2023[3] - The company reported a net cash used in operating activities of$44.8 million for the nine months ended September 30, 2024, compared to $37.8 million for the same period in 2023[15] Cash and Investments - Cash, cash equivalents, and investments totaled$221.2 million as of September 30, 2024[4] - Cash, cash equivalents, and restricted cash at the end of the period were $5.4 million, down from$75.1 million at the end of Q3 2023[15] Expenses - Research and development expenses for Q3 2024 were $12.3 million, up from$12.0 million in Q3 2023[13] - General and administrative expenses for Q3 2024 were $6.8 million, down from$7.1 million in Q3 2023[13] Assets and Liabilities - Total assets decreased to $259.7 million as of September 30, 2024, from$305.6 million at the end of 2023[11] - Total liabilities decreased to $36.3 million as of September 30, 2024, from$40.2 million at the end of 2023[11] Strategic Focus - The company is focused on advancing its single-molecule proteome analysis platform, which is expected to enhance research capabilities in proteomics[2]